NuCana PLC Market Cap ($4.16 Million)
Market Cap & Net Worth: NuCana PLC (NCNA)
NuCana PLC market cap. NuCana PLC (NASDAQ:NCNA) has a market capitalization of $4.16 Million ($4.16 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28872 globally and #5928 in its home market, demonstrating a -3.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NuCana PLC's stock price $1.00 by its total outstanding shares 4161971 (4.16 Million). Also see NCNA operating cash flow for how efficiently the company converts equity into cash flow.
NuCana PLC Market Cap History (2017–2026)
NuCana PLC market cap history from 2017 to 2026. Data shows change from $1.05 Billion to $4.16 Million (-48.27% CAGR). Check NuCana PLC (NCNA) share price today for real-time trading data and today's change.
Index Memberships
NuCana PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #831 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2657 of 3165 |
Weight: NuCana PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NuCana PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NuCana PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of NuCana PLC to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3717.10x
NuCana PLC's market cap is 3717.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.05 Billion | $283.00K | -$23.09 Million | 3717.10x | N/A |
Competitor Companies of NCNA by Market Capitalization
Companies near NuCana PLC in the global market cap rankings as of November 4, 2026. Also see NCNA asset base for a full breakdown of the balance sheet.
Key companies related to NuCana PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of NuCana PLC (2017–2026)
Market capitalization of NuCana PLC from 2017 to today. Between 2017 and today, NuCana PLC's market cap moved from $1.05 Billion to $ 4.16 Million, with a yearly change of -48.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.16 Million | -72.22% |
| 2025 | $14.98 Million | +202.52% |
| 2024 | $4.95 Million | -83.91% |
| 2023 | $30.78 Million | -55.18% |
| 2022 | $68.67 Million | -72.27% |
| 2021 | $247.64 Million | -46.99% |
| 2020 | $467.18 Million | -26.39% |
| 2019 | $634.70 Million | -57.93% |
| 2018 | $1.51 Billion | +43.42% |
| 2017 | $1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of NuCana PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.16 Million USD |
| MoneyControl | $4.16 Million USD |
| MarketWatch | $4.16 Million USD |
| marketcap.company | $4.16 Million USD |
| Reuters | $4.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metab… Read more